🟢 New in Current Filing Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial results. 🔒

🟢 New in Current Filing RESULTS OF OPERATIONS 🔒

🟢 New in Current Filing Business Combinations 🔒

🟢 New in Current Filing Noncontrolling 🔒

🟢 New in Current Filing Year ended June 30, 🔒

🟢 New in Current Filing Year Ended June 30, 🔒

🔴 No Match in Current Filing Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners. 🔒

🔴 No Match in Current Filing Business Strategy Update 🔒

🔴 No Match in Current Filing CRITICAL ACCOUNTING POLICIES 🔒

🔴 No Match in Current Filing On July 1, 2022, the Company completed the acquisition of Namocell, Inc. for approximately $100 million, plus contingent consideration of up to $25 million upon the achievement of certain future milestones. 🔒

🔴 No Match in Current Filing Year ended June 30, 🔒

🔴 No Match in Current Filing Year Ended June 30, 🔒

🔴 No Match in Current Filing Note 10. Share-based Compensation and Other Benefit Plans: 🔒

🔴 No Match in Current Filing Year Ended June 30, 🔒

🔴 No Match in Current Filing Life (years) 🔒

🔴 No Match in Current Filing Contractual 🔒

🟡 Modified The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results. 🔒

🟡 Modified Note 7. Leases: 🔒

🟡 Modified Other Non-Operating Income / (Expense), Net 🔒

🟡 Modified Note 2. Revenue Recognition: 🔒

🟡 Modified Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners. 🔒

🟡 Modified CRITICAL ACCOUNTING POLICIES 🔒

🟡 Modified Research and Development Expenses 🔒

🟡 Modified Issuer Purchases of Equity Securities 🔒

🟡 Modified Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information: 🔒

🟡 Modified Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results. 🔒

🟡 Modified Note 5. Fair Value Measurements: 🔒

🟡 Modified Holders of Common Stock and Dividends Paid 🔒

🟡 Modified Recently Adopted Accounting Pronouncements 🔒

🟡 Modified Stock Performance Graph 🔒